|
1
|
Yang P, Wang Y, Peng X, You G, Zhang W, Yan W, Bao Z, Wang Y, Qiu X and Jiang T: Management and survival rates in patients with glioma in China (2004–2010): A retrospective study from a single-institution. J Neurooncol. 113:259–266. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng S and Li Z: Identification of a cullin5-RING E3 ligase transcriptome signature in glioblastoma multiforme. Aging (Albany NY). 12:17380–17392. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xu B, Mei J, Ji W, Huo Z, Bian Z, Jiao J, Li X, Sun J and Shao J: MicroRNAs involved in the EGFR pathway in glioblastoma. Biomed Pharmacother. 134:1111152021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fedele M, Cerchia L, Pegoraro S, Sgarra R and Manfioletti G: Proneural-mesenchymal transition: Phenotypic plasticity to acquire multitherapy resistance in glioblastoma. Int J Mol Sci. 20:27462019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamini B: NF-κB, mesenchymal differentiation and glioblastoma. Cells. 7:1252018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, et al: The transcriptional network for mesenchymal transformation of brain tumours. Nature. 463:318–325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bhat KP, Salazar KL, Balasubramaniyan V, Wani K, Heathcock L, Hollingsworth F, James JD, Gumin J, Diefes KL, Kim SH, et al: The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. Genes Dev. 25:2594–2609. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al: An integrated genomic analysis of human glioblastoma multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dimitrov L, Hong CS, Yang C, Zhuang Z and Heiss JD: New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma. Int J Med Sci. 12:201–213. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wesseling P, van den Bent M and Perry A: Oligodendroglioma: Pathology, molecular mechanisms and markers. Acta Neuropathol. 129:809–827. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kondo T: Molecular mechanisms involved in gliomagenesis. Brain Tumor Pathol. 34:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kile BT, Schulman BA, Alexander WS, Nicola NA, Martin HM and Hilton DJ: The SOCS box: A tale of destruction and degradation. Trends Biochem Sci. 27:235–241. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Urbantat RM, Blank A, Kremenetskaia I, Vajkoczy P, Acker G and Brandenburg S: The CXCL2/IL8/CXCR2 pathway is relevant for brain tumor Malignancy and Endothelial cell function. Int J Mol Sci. 22:26342021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu CH, Liu Y, Xiao LM, Chen LK, Zheng SY, Zeng EM, Li DH and Li YP: Silencing microRNA-221/222 cluster suppresses glioblastoma angiogenesis by suppressor of cytokine signaling-3-dependent JAK/STAT pathway. J Cell Physiol. 234:22272–22284. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I and Yoshimura A: CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem. 275:29338–29347. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baetz A, Frey M, Heeg K and Dalpke AH: Suppressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells. J Biol Chem. 279:54708–54715. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, et al: Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol. 169:2199–2208. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cacalano NA, Sanden D and Johnston JA: Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras. Nat Cell Biol. 3:460–465. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kazi JU, Kabir NN and Soh JW: Bioinformatic prediction and analysis of eukaryotic protein kinases in the rat genome. Gene. 410:147–153. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E and Wang L: PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget. 7:33440–33450. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ and Harper JW: The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev. 13:270–283. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McFarland BC, Gray GK, Nozell SE, Hong SW and Benveniste EN: Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells. Mol Cancer Res. 11:494–505. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qin H, Wilson CA, Roberts KL, Baker BJ, Zhao X and Benveniste EN: IL-10 inhibits lipopolysaccharide-induced CD40 gene expression through induction of suppressor of cytokine signaling-3. J Immunol. 177:7761–7771. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Baker BJ, Akhtar LN and Benveniste EN: SOCS1 and SOCS3 in the control of CNS immunity. Trends Immunol. 30:392–400. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kazi JU, Kabir NN, Flores-Morales A and Rönnstrand L: SOCS proteins in regulation of receptor tyrosine kinase signaling. Cell Mol Life Sci. 71:3297–3310. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lindemann C, Hackmann O, Delic S, Schmidt N, Reifenberger G and Riemenschneider MJ: SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation. Acta Neuropathol. 122:241–251. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dai L, Li Z, Tao Y, Liang W, Hu W, Zhou S, Fu X and Wang X: Emerging roles of suppressor of cytokine signaling 3 in human cancers. Biomed Pharmacother. 144:1122622021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yoshimura A, Ohkubo T, Kiguchi T, Jenkins NA, Gilbert DJ, Copeland NG, Hara T and Miyajima A: A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors. EMBO J. 14:2816–2826. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, Gonda TJ, Alexander WS, Metcalf D, Nicola NA and Hilton DJ: A family of cytokine-inducible inhibitors of signalling. Nature. 387:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nicholson SE and Hilton DJ: The SOCS proteins: A new family of negative regulators of signal transduction. J Leukoc Biol. 63:665–668. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, Sprigg NS, Starr R, Nicholson SE, Metcalf D and Nicola NA: Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA. 95:114–119. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ou-Yang Q, He X, Yang A, Li B and Xu M: Interference with NTSR1 expression exerts an anti-invasion effect via the Jun/miR-494/SOCS6 axis of glioblastoma cells. Cell Physiol Biochem. 49:2382–2395. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qu Y, Qi L, Hao L and Zhu J: Upregulation of circ-ASPH contributes to glioma cell proliferation and aggressiveness by targeting the miR-599/AR/SOCS2-AS1 signaling pathway. Oncol Lett. 21:3882021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bullock AN, Debreczeni JE, Edwards AM, Sundström M and Knapp S: Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proc Natl Acad Sci USA. 103:7637–7642. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Babon JJ, McManus EJ, Yao S, DeSouza DP, Mielke LA, Sprigg NS, Willson TA, Hilton DJ, Nicola NA, Baca M, et al: The structure of SOCS3 reveals the basis of the extended SH2 domain function and identifies an unstructured insertion that regulates stability. Mol Cell. 22:205–216. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Linossi EM and Nicholson SE: The SOCS box-adapting proteins for ubiquitination and proteasomal degradation. IUBMB Life. 64:316–323. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Piessevaux J, Lavens D, Peelman F and Tavernier J: The many faces of the SOCS box. Cytokine Growth Factor Rev. 19:371–381. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bulatov E, Martin EM, Chatterjee S, Knebel A, Shimamura S, Konijnenberg A, Johnson C, Zinn N, Grandi P, Sobott F and Ciulli A: Biophysical studies on interactions and assembly of full-size E3 ubiquitin ligase: Suppressor of cytokine signaling 2 (SOCS2)-elongin BC-cullin 5-ring box protein 2 (RBX2). J Biol Chem. 290:4178–4191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cooper JA, Kaneko T and Li SS: Cell regulation by phosphotyrosine-targeted ubiquitin ligases. Mol Cell Biol. 35:1886–1897. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Babon JJ, Sabo JK, Soetopo A, Yao S, Bailey MF, Zhang JG, Nicola NA and Norton RS: The SOCS box domain of SOCS3: Structure and interaction with the elonginBC-cullin5 ubiquitin ligase. J Mol Biol. 381:928–940. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Linossi EM, Calleja DJ and Nicholson SE: Understanding SOCS protein specificity. Growth Factors. 36:104–117. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rahaman SO, Vogelbaum MA and Haque SJ: Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: Involvement of IL-13 Ralpha2. Cancer Res. 65:2956–2963. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shuai K and Liu B: Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 3:900–911. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Qin H, Niyongere SA, Lee SJ, Baker BJ and Benveniste EN: Expression and functional significance of SOCS-1 and SOCS-3 in astrocytes. J Immunol. 181:3167–3176. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pauli EK, Schmolke M, Wolff T, Viemann D, Roth J, Bode JG and Ludwig S: Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. PLoS Pathog. 4:e10001962008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cohney SJ, Sanden D, Cacalano NA, Yoshimura A, Mui A, Migone TS and Johnston JA: SOCS-3 is tyrosine phosphorylated in response to interleukin-2 and suppresses STAT5 phosphorylation and lymphocyte proliferation. Mol Cell Biol. 19:4980–4988. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu LH, Li H, Cheng XX, Kong QY, Chen XY, Wu ML, Li Y, Liu J and Li C: Correlative analyses of the expression levels of PIAS3, p-SHP2, SOCS1 and SOCS3 with STAT3 activation in human astrocytomas. Mol Med Rep. 15:847–852. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhou H, Miki R, Eeva M, Fike F, Seligson D, Yang L, Yoshimura A, Teitell MA, Jamieson CA and Cacalano NA: Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme. Clin Cancer Res. 13:2344–2353. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Martini M, Pallini R, Luongo G, Cenci T, Lucantoni C and Larocca LM: Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int J Cancer. 123:2955–2960. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lee H, Hwang SJ, Kim HR, Shin CH, Choi KH, Joung JG and Kim HH: Neurofibromatosis 2 (NF2) controls the invasiveness of glioblastoma through YAP-dependent expression of CYR61/CCN1 and miR-296-3p. Biochim Biophys Acta. 1859:599–611. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Khalighfard S, Kalhori MR, Haddad P, Khori V and Alizadeh AM: Enhancement of resistance to chemo-radiation by hsa-miR-1290 expression in glioblastoma cells. Eur J Pharmacol. 880:1731442020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Liu Z, Wang J, Tong H, Wang X, Zhang D and Fan Q: LINC00668 Modulates SOCS5 expression through competitively sponging miR-518c-3p to facilitate glioma cell proliferation. Neurochem Res. 45:1614–1625. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang D, Ma L, Wang B, Liu J and Wei W: E3 ubiquitin ligases in cancer and implications for therapies. Cancer Metastasis Rev. 36:683–702. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lammering G, Valerie K, Lin PS, Hewit TH and Schmidt-Ullrich RK: Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol. 72:267–273. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhao Y and Sun Y: Cullin-RING Ligases as attractive anti-cancer targets. Curr Pharm Des. 19:3215–3225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Rawlings JS, Rosler KM and Harrison DA: The JAK/STAT signaling pathway. J Cell Sci. 117((Pt 8)): 1281–1283. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wilkinson KD: Protein ubiquitination: A regulatory post-translational modification. Anticancer Drug Des. 2:211–229. 1987.PubMed/NCBI
|
|
59
|
Mosesson Y, Mills GB and Yarden Y: Derailed endocytosis: An emerging feature of cancer. Nat Rev Cancer. 8:835–850. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Jin WL, Mao XY and Qiu GZ: Targeting deubiquitinating enzymes in glioblastoma multiforme: Expectations and challenges. Med Res Rev. 37:627–661. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Scholz N, Kurian KM, Siebzehnrubl FA and Licchesi JDF: Targeting the ubiquitin system in glioblastoma. Front Oncol. 10:5740112020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
d'Azzo A, Bongiovanni A and Nastasi T: E3 ubiquitin ligases as regulators of membrane protein trafficking and degradation. Traffic. 6:429–441. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kamura T, Maenaka K, Kotoshiba S, Matsumoto M, Kohda D, Conaway RC, Conaway JW and Nakayama KI: VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev. 18:3055–3065. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kile BT and Alexander WS: The suppressors of cytokine signalling (SOCS). Cell Mol Life Sci. 58:1627–1635. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhao Y, Xiong X and Sun Y: Cullin-RING Ligase 5: Functional characterization and its role in human cancers. Semin Cancer Biol. 67:61–79. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Inagaki-Ohara K, Kondo T, Ito M and Yoshimura A: SOCS, inflammation, and cancer. JAKSTAT. 2:e240532013.PubMed/NCBI
|
|
67
|
Humphreys LM, Smith P, Chen Z, Fouad S and D'Angiolella V: The role of E3 ubiquitin ligases in the development and progression of glioblastoma. Cell Death Differ. 28:522–537. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhang JG, Farley A, Nicholson SE, Willson TA, Zugaro LM, Simpson RJ, Moritz RL, Cary D, Richardson R, Hausmann G, et al: The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci USA. 96:2071–2076. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: A model for targeted therapy. Clin Cancer Res. 12:5268–5272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Xia L, Wang L, Chung AS, Ivanov SS, Ling MY, Dragoi AM, Platt A, Gilmer TM, Fu XY and Chin YE: Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation. J Biol Chem. 277:30716–30723. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Goldshmit Y, Walters CE, Scott HJ, Greenhalgh CJ and Turnley AM: SOCS2 induces neurite outgrowth by regulation of epidermal growth factor receptor activation. J Biol Chem. 279:16349–16355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Bullock AN, Rodriguez MC, Debreczeni JE, Songyang Z and Knapp S: Structure of the SOCS4-ElonginB/C complex reveals a distinct SOCS box interface and the molecular basis for SOCS-dependent EGFR degradation. Structure. 15:1493–1504. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Kario E, Marmor MD, Adamsky K, Citri A, Amit I, Amariglio N, Rechavi G and Yarden Y: Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem. 280:7038–7048. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al: The somatic genomic landscape of glioblastoma. Cell. 155:462–77. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Gao T, Furnari F and Newton AC: PHLPP: A phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell. 18:13–24. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Li X, Liu J and Gao T: Beta-TrCP-mediated ubiquitination and degradation of PHLPP1 are negatively regulated by Akt. Mol Cell Biol. 29:6192–6205. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Ventero MP, Fuentes-Baile M, Quereda C, Perez-Valeciano E, Alenda C, Garcia-Morales P, Esposito D, Dorado P, Manuel Barbera V and Saceda M: Radiotherapy resistance acquisition in Glioblastoma. Role of SOCS1 and SOCS3. PLoS One. 14:e02125812019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O and Woodgett JR: Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 406:86–90. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
King TD, Bijur GN and Jope RS: Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res. 919:106–114. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Lin J, Song T, Li C and Mao W: GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer. Biochim Biophys Acta Mol Cell Res. 1867:1186592010. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Lawrence T: The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 1:a0016512009. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Ohgaki H and Kleihues P: Epidemiology and etiology of gliomas. Acta Neuropathol. 109:93–108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Rao RD and James CD: Altered molecular pathways in gliomas: An overview of clinically relevant issues. Semin Oncol. 31:595–604. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Brantley EC and Benveniste EN: Signal transducer and activator of transcription-3: A molecular hub for signaling pathways in gliomas. Mol Cancer Res. 6:675–684. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Brantley EC, Nabors LB, Gillespie GY, Choi YH, Palmer CA, Harrison K, Roarty K and Benveniste EN: Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: Implications for STAT-3 activation and gene expression. Clin Cancer Res. 14:4694–4704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Schaefer LK, Ren Z, Fuller GN and Schaefer TS: Constitutive activation of Stat3alpha in brain tumors: Localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene. 21:2058–2065. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Yoshimura A, Naka T and Kubo M: SOCS proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 7:454–465. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Qin H, Roberts KL, Niyongere SA, Cong Y, Elson CO and Benveniste EN: Molecular mechanism of lipopolysaccharide-induced SOCS-3 gene expression in macrophages and microglia. J Immunol. 179:5966–5976. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Ramana CV, Kumar A and Enelow R: Stat1-independent induction of SOCS-3 by interferon-gamma is mediated by sustained activation of Stat3 in mouse embryonic fibroblasts. Biochem Biophys Res Commun. 327:727–733. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA and Haque SJ: Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene. 21:8404–8413. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN and Nutt CL: Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: Correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol. 65:1181–1188. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Weissenberger J, Loeffler S, Kappeler A, Kopf M, Lukes A, Afanasieva TA, Aguzzi A and Weis J: IL-6 is required for glioma development in a mouse model. Oncogene. 23:3308–3316. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Repovic P, Fears CY, Gladson CL and Benveniste EN: Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells. Oncogene. 22:8117–8124. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Loeffler S, Fayard B, Weis J and Weissenberger J: Interleukin-6 induces transcriptional activation of vascular endothelial growth factor (VEGF) in astrocytes in vivo and regulates VEGF promoter activity in glioblastoma cells via direct interaction between STAT3 and Sp1. Int J Cancer. 115:202–213. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Keewan E and Matlawska-Wasowska K: The emerging role of suppressors of cytokine signaling (SOCS) in the development and progression of leukemia. Cancers (Basel). 13:40002021. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Yokogami K, Yamashita S and Takeshima HJBtp: Hypoxia-induced decreases in SOCS3 increase STAT3 activation and upregulate VEGF gene expression. Brain Tumor Pathol. 30:135–143. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer. 9:798–809. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Bassères DS and Baldwin AS: Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 25:6817–6830. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Hoffmann A and Baltimore D: Circuitry of nuclear factor kappaB signaling. Immunol Rev. 210:171–186. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Karin M: NF-kappaB and cancer: Mechanisms and targets. Mol Carcinog. 45:355–361. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Perkins ND: The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer. 12:121–132. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Gray GK, McFarland BC, Nozell SE and Benveniste EN: NF-κB and STAT3 in glioblastoma: Therapeutic targets coming of age. Expert Rev Neurother. 14:1293–1306. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Akhtar LN, Qin H, Muldowney MT, Yanagisawa LL, Kutsch O, Clements JE and Benveniste EN: Suppressor of cytokine signaling 3 inhibits antiviral IFN-beta signaling to enhance HIV-1 replication in macrophages. J Immunol. 185:2393–2404. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Li X, Massa PE, Hanidu A, Peet GW, Aro P, Savitt A, Mische S, Li J and Marcu KB: IKKalpha, IKKbeta, and NEMO/IKKgamma are each required for the NF-kappa B-mediated inflammatory response program. J Biol Chem. 277:45129–45140. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Chen Z and Hambardzumyan D: Immune microenvironment in glioblastoma subtypes. Front Immunol. 9:10042018. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Tamiya T, Kashiwagi I, Takahashi R, Yasukawa H and Yoshimura A: Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: Regulation of T-cell inflammation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol. 31:980–985. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Wang Z: ErbB receptors and cancer. Methods Mol Biol. 1652:3–35. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Kang XC, Chen ML, Yang F, Gao BQ, Yang QH, Zheng WW and Hao S: Promoter methylation and expression of SOCS-1 affect clinical outcome and epithelial-mesenchymal transition in colorectal cancer. Biomed Pharmacother. 80:23–29. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Cui M, Sun J, Hou J, Fang T, Wang X, Ge C, Zhao F, Chen T, Xie H, Cui Y, et al: The suppressor of cytokine signaling 2 (SOCS2) inhibits tumor metastasis in hepatocellular carcinoma. Tumour Biol. 37:13521–13531. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zhang L, Li J, Li L, Zhang J, Wang X, Yang C, Li Y, Lan F and Lin P: IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway. Carcinogenesis. 35:1330–1340. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Lee H, Shin CH, Kim HR, Choi KH and Kim HH: MicroRNA-296-5p promotes invasiveness through downregulation of nerve growth factor receptor and caspase-8. Mol Cells. 40:254–261. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Sutherland KD, Lindeman GJ, Choong DY, Wittlin S, Brentzell L, Phillips W, Campbell IG and Visvader JE: Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene. 23:7726–7733. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Quesnelle KM, Boehm AL and Grandis JR: STAT-mediated EGFR signaling in cancer. J Cell Biochem. 102:311–319. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
You JS and Jones PA: Cancer genetics and epigenetics: Two sides of the same coin? Cancer Cell. 22:9–20. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Feng Y, Wang Z, Bao Z, Yan W, You G, Wang Y, Hu H, Zhang W, Zhang Q and Jiang T: SOCS3 promoter hypermethylation is a favorable prognosticator and a novel indicator for G-CIMP-positive GBM patients. PLoS One. 9:e918292014. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Barreau O, Assié G, Wilmot-Roussel H, Ragazzon B, Baudry C, Perlemoine K, René-Corail F, Bertagna X, Dousset B, Hamzaoui N, et al: Identification of a CpG island methylator phenotype in adrenocortical carcinomas. J Clin Endocrinol Metab. 98:E174–E184. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 17:510–522. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Kloten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, Veeck J, Hartmann A, Knüchel R and Dahl E: Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res. 15:R42013. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Wolff EM, Byun HM, Han HF, Sharma S, Nichols PW, Siegmund KD, Yang AS, Jones PA and Liang G: Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet. 6:e10009172010. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Fourouclas N, Li J, Gilby DC, Campbell PJ, Beer PA, Boyd EM, Goodeve AC, Bareford D, Harrison CN, Reilly JT, et al: Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica. 93:1635–1644. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Thomas SJ, Snowden JA, Zeidler MP and Danson SJ: The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer. 113:365–371. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Trengove MC and Ward AC: SOCS proteins in development and disease. Am J Clin Exp Immunol. 2:1–29. 2013.PubMed/NCBI
|
|
123
|
Tanaka T, Arai M, Jiang X, Sugaya S, Kanda T, Fujii K, Kita K, Sugita K, Imazeki F, Miyashita T, et al: Downregulation of microRNA-431 by human interferon-β inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6. Int J Oncol. 44:1685–1690. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Cao H, Li X, Wang F, Zhang Y, Xiong Y and Yang Q: Phytochemical-mediated glioma targeted treatment: Drug resistance and novel delivery systems. Curr Med Chem. 27:599–629. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Chistiakov DA and Chekhonin VP: Contribution of microRNAs to radio- and chemoresistance of brain tumors and their therapeutic potential. Eur J Pharmacol. 684:8–18. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Lammering G, Hewit TH, Valerie K, Contessa JN, Amorino GP, Dent P and Schmidt-Ullrich RK: EGFRvIII-mediated radioresistance through a strong cytoprotective response. Oncogene. 22:5545–5553. 2003. View Article : Google Scholar : PubMed/NCBI
|
